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ac1 and Connective
issue Growth Factor
he Missing Link Between
trial Remodeling and the
athogenesis of Atrial Fibrillation?*
ames K. Liao, MD
oston, Massachusetts
trial fibrillation (AF) is the most common type of cardiac
rrhythmia and a major cause of morbidity and mortality
1). AF typically occurs after cardiac surgery or in patients
ith hypertension or ischemic, valvular, structural, or met-
bolic heart disease (2). In some cases, AF has no clear
tiology, which is often referred to as lone or idiopathic AF.
evertheless, most patients with AF have increased left
trial size (3), and AF patients with left atrial enlargement
ave poorer cardiovascular prognosis compared with pa-
ients who have normal left atrial dimensions (4). However,
eft atrium enlargement could also be a consequence of AF
5). Histological biopsy studies in patients with lone AF
evealed increased atrial inflammation and fibrosis (6).
ndeed, fibrosis and extracellular matrix remodeling are
mportant components of left atrial enlargement (7,8), and
ncreased left atrial volume is a strong predictor of post-
perative AF (9). These findings suggest that left atrial
brosis could contribute to the pathogenesis of AF. How-
ver, the precise signaling pathways that mediate these
hanges in the left atrium are not known.
See page 469
To obtain greater insights into the pathophysiological
echanism of AF, Adam et al. (10), in this issue of the
ournal, performed transcriptional profiling analysis on tissues
rom the left atrial appendage of patients in sinus rhythm (SR)
r chronic AF undergoing mitral valve surgery. Despite similar
eft atrial dimensions, patients with AF were found to have
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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erck, and Pfizer.ncreased expression of genes that are involved in interstitial
brosis such as collagen and connective tissue growth factor
CTGF). This was associated with increased expression of
dherens junction protein, N-cadherin, and gap junction
rotein, connexin-43, which are important mediators of
lectrophysiological properties of the left atrium. The ex-
ression of connexin-40, however, was unchanged, which is
n contrast to other clinical studies showing that AF is
ssociated with somatic mutation or increased expression of
onnexin-40 (11,12).
Previous studies have shown that angiotensin II activates
ac1, leading to collagen synthesis, fibrosis, and atrial
emodeling (13). Interestingly, angiotensin receptor block-
rs have been shown to prevent new-onset and recurrent AF
14,15). The small guanosine triphosphate (GTP)-binding
rotein, Rac1, is a member of the Rho GTPase superfamily
f intracellular signal transducers, which is involved in the
egulation of nicotinamide adenine dinucleotide phosphate
NADPH)-dependent oxidative stress (16). The activity of
ac1 and Rac1-mediated NADPH-derived superoxide an-
on production are increased in the atria of patients and
nimals with AF (17,18). Furthermore, Rac1 mediates the
ownstream localization of connexin-43 by N-cadherin (19).
hus, it is likely that the up-regulation of Rac1 contributes
o the pathogenesis of AF. To determine whether Rac1
ediates atrial remodeling through increased expression of
TGF, N-cadherin, and connexin-43, the authors gener-
ted transgenic mice with cardiac-specific overexpression of
constitutive active Rac1 mutant, namely, RacET mice.
hey found that RacET mice exhibited increased expres-
ion of CTGF, N-adherin, connexin-43, and interstitial
brosis whether or not the mice were in SR or AF,
uggesting that increased Rac1 activity and not AF precedes
trial remodeling.
Because Rac1 requires post-translational modification by
soprenylation for proper intracellular trafficking and func-
ion, Rac1 could potentially be inhibited by 3-hydroxy-3-
ethylglutaryl-coenzyme A reductase inhibitors or statins,
hich block isoprenoid synthesis (20). Indeed, statins in-
ibit angiotensin II-induced increased myocardial oxidative
tress and cardiac remodeling by inhibiting Rac1-mediated
ADPH oxidase activity (21,22). Furthermore, statin
herapy is associated with reduced incidence of AF in
ost-operative patients (23). Consistent with these find-
ngs, Adam et al. (10) found that treatment of RacET
ice with rosuvastatin decreased the expression of
TGF, N-cadherin, and connexin-43, and reduced the
ncidence of AF. Thus, these results suggest that inhibition
f angiotensin II-induced Rac1 activity with angiotensin
eceptor blockers, Rac1 inhibitors, or statins may have
herapeutic benefits in the prevention of atrial remodeling
nd the subsequent development of AF.
Although the results of this study support the conclusion
hat Rac1 and CTGF are involved in the pathogenesis of
F, the causality between Rac1, CTGF, and AF in humans
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Increased CTGF in AF February 2, 2010:481–2emains unclear. For example, animals treated with angio-
ensin II exhibit increased myocardial Rac1 activity, and
ardiac fibrosis develops, but not AF (22). Also, AF does
ot develop in most of the RacET mice, despite increases in
he expression of CTGF, N-cadherin, and connexin-43,
nd interstitial fibrosis comparable to those of RacET mice
hat do have AF. Furthermore, it is unlikely that there are any
athological conditions in humans where AF is associated with
30-fold increase in Rac1 expression similar to what was
bserved in the RacET mice used in this study. Finally, thus
ar, genetic mapping studies of patients who are more or less
usceptible to or at risk for AF have not localized any
utations to the Rac1 locus, which is located on chromosome
p22 (24,25). Thus, the general applicability of these findings
o patients with AF of various etiologies is uncertain.
The beneficial effects of statins on atrial remodeling and AF
re suggestive of Rac1, but because statins could also inhibit
ther isoprenoid-dependent pathways, such as the Ras and
ho/Rho kinase (ROCK) pathways, their inhibitory effects on
trial fibrosis and AF may not be due entirely to Rac1
nhibition. Indeed, deletion or inhibition of ROCK1 also leads
o decreased angiotensin II-induced CTGF expression and
ardiac fibrosis (26,27). Thus, the potential benefits of statin
herapy in AF may extend beyond their inhibitory effects on
ac1. For these reasons, it would probably have been more
efinitive to use a genetic loss-of-function rather than a
ain-of-function model of Rac1 to demonstrate that Rac1 is
bligatory for the development of AF. Thus, further studies are
equired to determine whether increased Rac1 activity and
TGF expression are necessary and/or sufficient to produce
F under various pathological conditions that are associated
ith AF in humans. Nevertheless, these findings do provide
ome of the mechanistic basis for the clinical benefits of
ngiotensin receptor blockers or statins in patients with AF.
hether specific Rac1 inhibitors will have similar therapeutic
enefits for patients with AF remains to be determined.
eprint requests and correspondence: Dr. James K. Liao, Brigham
Women’s Hospital, 65 Landsdowne Street, Room 275, Cam-
ridge, Massachusetts 02139. E-mail: jliao@rics.bwh.harvard.edu.
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